Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2004 2
2005 3
2006 3
2007 2
2010 1
2016 3
2018 1
2019 1
2021 1
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
The Nitrogen Mustards.
Highley MS, Landuyt B, Prenen H, Harper PG, De Bruijn EA. Highley MS, et al. Pharmacol Rev. 2022 Jul;74(3):552-599. doi: 10.1124/pharmrev.120.000121. Pharmacol Rev. 2022. PMID: 35710137 Review.
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Brown JE, Royle KL, Gregory W, Ralph C, Maraveyas A, Din O, Eisen T, Nathan P, Powles T, Griffiths R, Jones R, Vasudev N, Wheater M, Hamid A, Waddell T, McMenemin R, Patel P, Larkin J, Faust G, Martin A, Swain J, Bestall J, McCabe C, Meads D, Goh V, Min Wah T, Brown J, Hewison J, Selby P, Collinson F; STAR Investigators. Brown JE, et al. Lancet Oncol. 2023 Mar;24(3):213-227. doi: 10.1016/S1470-2045(22)00793-8. Epub 2023 Feb 13. Lancet Oncol. 2023. PMID: 36796394 Free article. Clinical Trial.
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM).
Dayimu A, Gupta A, Matin RN, Nobes J, Board R, Payne M, Rao A, Fusi A, Danson S, Eccles B, Carser J, Brown CO, Steven N, Bhattacharyya M, Brown E, Gonzalez M, Highley M, Pickering L, Kumar S, Waterston A, Burghel G, Demain L, Baker E, Wulff J, Qian W, Twelves S, Middleton M, Corrie P. Dayimu A, et al. Among authors: highley m. Eur J Cancer. 2024 Jan;196:113455. doi: 10.1016/j.ejca.2023.113455. Epub 2023 Nov 24. Eur J Cancer. 2024. PMID: 38029480 Free article. Clinical Trial.
Vascular endothelial growth factor and angiogenesis.
Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Hoeben A, et al. Among authors: highley ms. Pharmacol Rev. 2004 Dec;56(4):549-80. doi: 10.1124/pr.56.4.3. Pharmacol Rev. 2004. PMID: 15602010 Review.
Pharmacology of anticancer drugs in the elderly population.
Wildiers H, Highley MS, de Bruijn EA, van Oosterom AT. Wildiers H, et al. Among authors: highley ms. Clin Pharmacokinet. 2003;42(14):1213-42. doi: 10.2165/00003088-200342140-00003. Clin Pharmacokinet. 2003. PMID: 14606930 Review.
Runs of homozygosity and testicular cancer risk.
Loveday C, Sud A, Litchfield K, Levy M, Holroyd A, Broderick P, Kote-Jarai Z, Dunning AM, Muir K, Peto J, Eeles R, Easton DF, Dudakia D, Orr N, Pashayan N; UK Testicular Cancer Collaboration; PRACTICAL Consortium; Reid A, Huddart RA, Houlston RS, Turnbull C. Loveday C, et al. Andrology. 2019 Jul;7(4):555-564. doi: 10.1111/andr.12667. Andrology. 2019. PMID: 31310061 Free article.
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).
Joffe JK, Cafferty FH, Murphy L, Rustin GJS, Sohaib SA, Gabe R, Stenning SP, James E, Noor D, Wade S, Schiavone F, Swift S, Dunwoodie E, Hall M, Sharma A, Braybrooke J, Shamash J, Logue J, Taylor HH, Hennig I, White J, Rudman S, Worlding J, Bloomfield D, Faust G, Glen H, Jones R, Seckl M, MacDonald G, Sreenivasan T, Kumar S, Protheroe A, Venkitaraman R, Mazhar D, Coyle V, Highley M, Geldart T, Laing R, Kaplan RS, Huddart RA; TRISST Trial Management Group and Investigators. Joffe JK, et al. Among authors: highley m. J Clin Oncol. 2022 Aug 1;40(22):2468-2478. doi: 10.1200/JCO.21.01199. Epub 2022 Mar 17. J Clin Oncol. 2022. PMID: 35298280 Free PMC article. Clinical Trial.
Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma.
Oudard S, Benhamouda N, Escudier B, Ravel P, Tran T, Levionnois E, Negrier S, Barthelemy P, Berdah JF, Gross-Goupil M, Sternberg CN, Bono P, Porta C, De Giorgi U, Parikh O, Hawkins R, Highley M, Wilke J, Decker T, Tanchot C, Gey A, Terme M, Tartour E. Oudard S, et al. Among authors: highley m. Cells. 2021 Dec 22;11(1):17. doi: 10.3390/cells11010017. Cells. 2021. PMID: 35011579 Free PMC article. Clinical Trial.
26 results